Drug intelligence / Profile preview

Awake-103

Development stage: Preclinical
Lead developer: Matter Bio
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

Awake-103 is an immunotherapy candidate in the discovery stage, developed by Matter Bio for the treatment of glioblastoma. It utilizes the LM-LLO-TT platform, which employs a live-attenuated *Listeria monocytogenes* (LM) vector to deliver a tetanus toxoid (TT) recall antigen fused to listeriolysin O (LLO). The therapy is designed to localize within the tumor microenvironment and present the tetanus antigen, thereby recruiting and activating pre-existing memory T cells—formed during prior routine tetanus vaccinations—to attack the tumor. This strategy aims to overcome the immunosuppressive nature of the glioblastoma environment by leveraging a potent, pre-existing immune memory rather than relying solely on the identification and priming of novel tumor-specific antigens.

Targets

Tetanus toxoid-specific T-cell receptor

Beyond the preview

Go deeper on Awake-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Awake-103.

Explore the full profile